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  N
o resource allocation decision 
occurs in a vacuum. The 
decision to fund any public 
health intervention implies that 
those funds will be unavailable for 
alternative uses that may confer greater 
or lesser beneﬁ  ts. Even when funds 
are earmarked for a speciﬁ  c purpose, 
such as providing antiretroviral 
therapy (ART), questions persist: 
should more money be spent on 
pharmaceuticals and less on laboratory 
tests that monitor treatment response? 
should treatments be targeted toward 
individuals with a wide spectrum of 
disease stages, or should treatments be 
targeted exclusively toward individuals 
with late-stage disease? 
    The purpose of cost-effectiveness 
analysis is to enable the health and 
economic value from a particular policy 
decision to be compared with the 
value from alternative decisions. While 
many factors other than health and 
economic value need to be considered 
in the formulation of health policy 
(for example, ensuring equality in 
access to health services), such value 
is an important consideration. The 
cost-effectiveness of highly active 
antiretroviral therapy (HAART) has 
been studied widely in resource-rich 
countries, but data from resource-poor 
environments have been scarce [1] or 
are out of date [2,3]. A new study by 
Motasim Badri and colleagues in   PLoS 
Medicine   on the cost-effectiveness of 
HAART in South Africa, therefore, 
constitutes an important addition to 
the literature [4].
    What is the Difference between 
Cost-Saving and Cost-Effective?
    When an intervention is judged cost-
effective, the implication is that its 
extra beneﬁ  ts justify its extra costs. If 
an intervention is cost-effective, this 
does not imply that the intervention is 
inexpensive (as the term “cost-effective” 
is often used in the vernacular) or 
cost-saving, since many cost-effective 
interventions are expensive. When an 
intervention is judged cost-saving, the 
intervention actually saves money.
    What Did the Authors Do and Find?
    The authors compared the costs and 
beneﬁ  ts between individuals receiving 
HAART and individuals not receiving 
HAART in a cohort of individuals 
infected with HIV in South Africa. 
Patients who participated in clinical 
trials and who received at least three 
ART drugs were considered the 
“treated arm” of the study. Patients 
who did not participate in these trials 
and who never had access to ART 
throughout the study period, but 
who received other HIV-related care, 
constituted the sample from which a 
“comparator” group was identiﬁ  ed.
    Because the authors did not conduct 
a randomized trial (they simply 
compared two cohorts of patients), 
they attempted to statistically adjust 
for important differences between the 
cohorts, such as age, socioeconomic 
status, and CD4 count. The authors 
concluded that individuals on HAART 
not only live longer but may have 
lower costs, depending on what price 
structure is assumed for HAART. With 
the current pricing of HAART (US$730 
per patient-year), the incremental 
cost-effectiveness of HAART versus no 
HAART was US$1,622 per additional 
life-year gained for individuals without 
AIDS. For individuals with AIDS, 
HAART would be cost-saving at 
that price. With the lower prices for 
HAART that would likely result from 
local manufacturing (US$181 per 
patient-year), the incremental cost-
effectiveness of HAART would be even 
more favorable at US$675 per life-year 
gained for individuals without AIDS, 
and HAART would remain cost-saving 
for individuals with AIDS. 
    The primary result of this analysis, an 
estimation of HAART’s additional cost 
per life-year gained, was judged for its 
economic attractiveness by comparing 
it with a guideline that considers the 
probable size of a country’s health 
budget (each disability-adjusted 
life-year should cost no more than 
two times the yearly gross domestic 
product). But this guideline is not an 
intrinsic tenet of cost-effectiveness 
analysis; rather, it resembles the “rule 
of thumb” suggested by the World 
Health Organization for interpreting 
incremental cost-effectiveness ratios 
(see chapter 5 of [5]). While this 
decision rule reﬂ  ects current disparities 
in health budgets, it may be criticized 
because it codiﬁ  es the notion that life 
in wealthier countries is worth more 
than life in poorer countries. 
  Strengths  and Weaknesses 
of the Study
    The primary strength of Badri and 
colleagues’ study is its incorporation 
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of prospectively measured cost 
and outcome data from the target 
population. An additional strength is its 
analysis of multiple-drug cost scenarios. 
Some cost-effectiveness studies 
presume a ﬁ  xed or narrow range of 
costs, which is inappropriate because 
prices may ﬂ  uctuate dramatically 
in an unanticipated fashion, with 
commensurately large ﬂ  uctuations 
in cost-effectiveness (e.g., the 20-fold 
decrease in the price of HAART that 
has been observed over the past ﬁ  ve 
years). 
    Limitations of the study include the 
lack of randomization, the questionable 
methods for adjusting for differences 
in patient characteristics, and the 
atypical methods for calculating life 
expectancies and costs. In particular, 
adjusting for CD4 count may have 
biased the analysis against HAART 
because individuals on HAART often 
experience rapid elevations in CD4 
count. Therefore, this analysis may have 
compared individuals off therapy with 
individuals on therapy who initially had 
lower CD4 counts, and were far sicker. 
Estimates of the life expectancies for 
patients taking or not taking HAART 
and for patients with AIDS versus 
no AIDS were based on median 
disease progression times, which were 
themselves estimated, rather than on 
areas under the survival curves. 
    Another limitation of the study was 
its brief time frame for considering 
costs. While individuals treated with 
HAART will initially have lower 
expenditures because of fewer 
hospitalizations, over their lifetimes 
their expenditures would be expected 
to increase as HAART becomes less 
effective due to resistance. These 
assumptions may have biased the 
analysis in favor of HAART. Finally, 
the authors’ decision to avoid 
discounting results is debatable, and 
may complicate comparing their results 
with those from other studies [6]. 
Discounting reﬂ  ects the notion that 
money or beneﬁ  ts that arrive today may 
be valued more than similar money or 
beneﬁ  ts that arrive in the future.
  Can  Cost-Effectiveness  Analysis 
Be Used to Deny Treatment?
    Some authors have invoked cost-
effectiveness analysis to question 
whether HAART should be provided 
in resource-poor areas [7–9]. However, 
it is important to note that cost-
effectiveness analysis by itself never 
implies that particular programs should 
or should not be funded—it only allows 
their relative beneﬁ  ts to be ranked. 
If health budgets are insufﬁ  cient, 
many health interventions that deliver 
great beneﬁ  ts will appear unfavorable 
because the budget will have been 
exhausted by competing uses that offer 
even greater value. Therefore, when 
an obviously beneﬁ  cial and life-saving 
service is deemed insufﬁ  ciently cost-
effective, it is an indictment of the 
parsimony of the health budget itself, 
not of the method of cost-effectiveness 
analysis.
  Policy  Implications
    The analysis by Badri and colleagues 
suggests that providing HAART in 
South Africa is likely to be relatively 
cost-effective for individuals without 
AIDS and even cost-saving for 
individuals with AIDS, assuming 
current drug prices and the “rule 
of thumb” for interpreting cost-
effectiveness ratios suggested by the 
World Health Organization. Moreover, 
if the price of HAART medications 
decreases further through local 
production, the cost-effectiveness 
of HAART for individuals without 
AIDS would become substantially 
more favorable. Therefore, these 
results support providing HAART to 
individuals with HIV in South Africa.   
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